The limited choice of available drugs, their toxicity (causing mortality in 5% of patients), and the disease’s growing unresponsiveness to drugs, make it imperative that new treatments are urgently developed.
The limited choice of available drugs, their toxicity (causing mortality in 5% of patients), and the disease’s growing unresponsiveness to drugs, make it imperative that new treatments are urgently developed.